We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

ACAPHA in Preventing Lung Cancer in Former Smokers With Bronchial Intraepithelial Neoplasia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00522197
First Posted: August 29, 2007
Last Update Posted: March 9, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
British Columbia Cancer Agency
  Purpose

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of ACAPHA, a combination of six herbs, may prevent lung cancer from forming in former smokers with bronchial intraepithelial neoplasia.

PURPOSE: This randomized phase II trial is studying the side effects and how well ACAPHA works in preventing lung cancer in former smokers with bronchial intraepithelial neoplasia.


Condition Intervention Phase
Lung Cancer Precancerous Condition Dietary Supplement: multi-herbal agent ACAPHA Dietary Supplement: Sugar Pill Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Phase II Trial of ACAPHA in Former Smokers With Intraepithelial Neoplasia

Resource links provided by NLM:


Further study details as provided by British Columbia Cancer Agency:

Primary Outcome Measures:
  • Efficacy and safety of multi-herbal agent ACAPHA as measured by combined histopathology and nuclear morphometry of intraepithelial neoplasia lesions [ Time Frame: 12 months ]

Secondary Outcome Measures:
  • Changes in the severity of dysplasia by bronchial biopsy [ Time Frame: 6 months ]
  • Changes in the morphometric index of sputum cells, bronchial biopsies, and epithelial cells in the bronchoalveolar lavage fluid (BAL) [ Time Frame: 12 months ]
  • MIB-1, bcl-2, and TUNEL immunostaining in the bronchial biopsies [ Time Frame: 12 months ]
  • Methylation biomarkers in the sputa, oral brush, and BAL cells [ Time Frame: 12 months ]
  • Gene expression analysis of RNA from bronchial brush cells [ Time Frame: 12 months ]
  • Volumetric measurement of CT scan-detected lung nodules before and after treatment [ Time Frame: 12 months ]

Enrollment: 90
Study Start Date: September 2002
Study Completion Date: November 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: ACAPHA Dietary Supplement: multi-herbal agent ACAPHA
Placebo Comparator: Sugar Pill Dietary Supplement: Sugar Pill

Detailed Description:

OBJECTIVES:

  • Determine the efficacy and safety of multi-herbal agent ACAPHA in former smokers with bronchial intraepithelial neoplasia.
  • Evaluate whether ACAPHA can modulate other surrogate endpoint biomarkers of aberrant methylation, cell cycle regulation, apoptosis, as well as phase I and II enzyme regulation.
  • Establish a library of in vivo confocal microendoscopy images with corresponding histopathology, nuclear morphometry, and other biomarker information to assess the potential of confocal microendoscopy as a nonbiopsy method in assessing the effect of chemoprevention agents.

OUTLINE: Patients are stratified according to gender. Patients are randomized to 1 of 2 arms.

  • Arm I: Patients receive oral multi-herbal agent ACAPHA twice daily for 6 months. Patients achieving a partial response receive an additional 6 months of ACAPHA.
  • Arm II: Patients receive oral placebo twice daily for 6 months. Patients achieving a partial response receive an additional 6 months of placebo. Patients with progressive disease receive ACAPHA twice daily for 6 months.

Patients undergo sputum cytology, oral and bronchial brushings, bronchoalveolar lavage, and bronchial tissue biopsies at baseline and at 6 and 12 months. Samples are analyzed for histopathological and morphometric cell changes; MIB-1 bcl-2, and TUNEL immunostaining; methylation biomarkers; and gene expression analysis of RNA.

After completion of study therapy, patients are followed at 1 and 6 months.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   45 Years to 74 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • One or more areas of bronchial intraepithelial neoplasia (IEN) (metaplasia/dysplasia) with a nuclear morphometry index > 1.36 and a surface diameter > 1.2 mm on autofluorescence bronchoscopy
  • Atypical sputum cells as determined by computer-assisted image analysis
  • Former smoker (i.e., stopped smoking at least 1 year ago) who has smoked at least 30 pack-years (i.e., 1 pack/day for 30 years or more)
  • Exhaled carbon monoxide level < 5 ppm
  • No invasive cancer on bronchoscopy or abnormal spiral chest CT scan suspicious of lung cancer

PATIENT CHARACTERISTICS:

  • ECOG performance status 0 or 1
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Normal renal function tests (BUN, creatinine, urinalysis)
  • Normal liver function tests (AST, ALT, bilirubin, alkaline phosphatase)
  • No chronic active hepatitis or liver cirrhosis
  • No acute bronchitis or pneumonia within the past month
  • No known reaction to xylocaine
  • No medical condition that, in the opinion of the investigator, could jeopardize the patient's safety during participation in the study, including any of the following:

    • Acute or chronic respiratory failure
    • Unstable angina
    • Uncontrolled congestive heart failure
    • Bleeding disorder

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00522197


Sponsors and Collaborators
British Columbia Cancer Agency
National Cancer Institute (NCI)
Investigators
Principal Investigator: Stephen Lam, MD British Columbia Cancer Agency
  More Information

Responsible Party: British Columbia Cancer Agency
ClinicalTrials.gov Identifier: NCT00522197     History of Changes
Other Study ID Numbers: CDR0000562055
U01CA096109 ( U.S. NIH Grant/Contract )
BCCA-H02-61177-A002
BCCA-R02-1177
First Submitted: August 28, 2007
First Posted: August 29, 2007
Last Update Posted: March 9, 2012
Last Verified: March 2012

Keywords provided by British Columbia Cancer Agency:
non-small cell lung cancer
small cell lung cancer
squamous lung dysplasia

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma in Situ
Precancerous Conditions
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type